NCT03054766View on ClinicalTrials.gov

Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 14, 2017

Primary Completion Date

February 1, 2018

Study Completion Date

January 28, 2019

Conditions
Branch Retinal Vein OcclusionRanibizumabLaser Photocoagulation
Interventions
PROCEDURE

Ranibizumab combined macular laser

subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.

DRUG

Ranibizumab

all subjections received 3+PRN ranibizumab injections by BCVA stabilization

Trial Locations (1)

100730

Beijing Hospital, Beijing

All Listed Sponsors
lead

Beijing Hospital

OTHER_GOV

NCT03054766 - Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO | Biotech Hunter | Biotech Hunter